273 related articles for article (PubMed ID: 17048248)
1. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
[TBL] [Abstract][Full Text] [Related]
2. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
4. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Harshman LC; Srinivas S
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
[TBL] [Abstract][Full Text] [Related]
5. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Margulis V; Matin SF; Wood CG
Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
[TBL] [Abstract][Full Text] [Related]
7. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention.
Hanley D; Gorelick PB; Elliott WJ; Broder MS; Saver JL; Kidwell CS; Fagan SC; Wilson A; Lennihan L; Schwer WA; Rubenstein LZ; Crowell RM; Haines SJ; Lopez CC; Zorowitz R; Dubois RW
J Stroke Cerebrovasc Dis; 2004; 13(5):196-207. PubMed ID: 17903976
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
Pantuck AJ; Belldegrun AS; Figlin RA
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology.
Gore ME; Bellmunt J; Eisen T; Escudier B; Mickisch G; Patard J; Porta C; Ravaud A; Schmidinger M; Schöffski P; Sternberg CN; Szczylik C; De Nigris E; Wheeler C; Kirpekar S
Eur J Cancer; 2012 May; 48(7):1038-47. PubMed ID: 22425264
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Healy KA; Marshall FF; Ogan K
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
[TBL] [Abstract][Full Text] [Related]
11. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.
Levy DA; Swanson DA; Slaton JW; Ellerhorst J; Dinney CP
J Urol; 1998 Apr; 159(4):1168-73. PubMed ID: 9507824
[TBL] [Abstract][Full Text] [Related]
12. Multimodality treatment of metastatic renal cell carcinoma.
Mickisch GH
Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
[TBL] [Abstract][Full Text] [Related]
13. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
Wood CG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
[TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
15. Management of metastatic renal cell carcinoma: current trends.
Mohammed A; Shergill I; Little B
Expert Rev Mol Diagn; 2009 Jan; 9(1):75-83. PubMed ID: 19099350
[TBL] [Abstract][Full Text] [Related]
16. Presurgical therapy in metastatic renal cell carcinoma.
Jonasch E
Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
Wood CG; Margulis V
Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
19. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
[TBL] [Abstract][Full Text] [Related]
20. Debulking nephrectomy in metastatic renal cancer.
Flanigan RC
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
